Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CochlearFRA:OC5 +1.01%65 Cash Ratio is 0.33 as of Dec. 2025, which is 39% below its 10-year median of 0.54. GuruFocus rates FRA:OC5 with a GF Score™ of 65/100 and a GF Value™ of €194.32 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Cochlear ranks worse than 76.46% on this metric.
Cochlear has a Cash Ratio of 0.33. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Cochlear's Cash Ratio or its related term are showing as below:
FRA:OC5'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.54 Max: 1.66
Current: 0.33
During the past 13 years, Cochlear's highest Cash Ratio was 1.66. The lowest was 0.21. And the median was 0.54.
FRA:OC5's Cash Ratio is ranked worse than 76.46% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.98
vs FRA:OC5: 0.33
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cochlear Cash Ratio Related Terms
Cochlear Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cochlear's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cochlear's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cochlear's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (FRA:OC5) has a Cash Ratio of 0.33 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cochlear and its competitors. This is 39% below median its historical median of 0.54. Over the past decade, Cochlear's Cash Ratio has ranged from 0.21 to 1.66. According to the industry distribution chart, Cochlear ranks #643 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 76.5%.
Is Cochlear's Cash Ratio too high?
Cochlear's current Cash Ratio of 0.33 is 39% below median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 1.66. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Cochlear's value of 0.33 is 66.3% below this industry median. Based on the distribution chart, Cochlear ranks #643 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cochlear has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #643 out of 841 companies for Cash Ratio. This places Cochlear in the lower half of its industry. The industry median Cash Ratio is 0.98. Cochlear's value of 0.33 is 66.3% below this benchmark. Historically, Cochlear's own Cash Ratio has ranged from 0.21 to 1.66 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 0.98, Cochlear has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current Cash Ratio of 0.33 is 66.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current Cash Ratio is 0.33, which is 39% below median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (FRA:OC5) is currently considered Significantly Undervalued. The stock's GF Value™ is €194.32, compared to a current price of €81.61 — trading 58% below its estimated fair value. The current Cash Ratio is 0.33, which is 39% below median its 10-year median of 0.54 and 66.3% below the Medical Devices & Instruments industry median of 0.98. Cochlear's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cochlear (FRA:OC5), the current Cash Ratio is 0.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (FRA:OC5) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of €81.61 is trading 58% below its estimated GF Value™ of €194.32.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for FRA:OC5:
Cash Ratio: 0.33 (39% below median its 10-year median of 0.54)
GF Value™: €194.32 vs. price of €81.61 (58% below fair value)
Industry Position: 66.3% below the Medical Devices & Instruments median (#643 of 841)
No single metric tells the full story. See the FRA:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
65GF Score
Get the complete analysis for FRA:OC5
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OC5 has been successfully added to your 
